Treatment of Early-Stage Non-Small Cell Lung Cancer - Final Assessment

Return to Enrollment Page

Primary Audience:

This activity is intended to meet the educational needs of oncologists and oncology advanced practice providers involved in the care of patients with early-stage NSCLC.

OVERVIEW

The following questions are designed to assess your gained knowledge and practice of patients with early-stage non-small cell lung cancer.

FACULTY

Patrick Forde, M.B.B.Ch.

Professor and Co-Director, Division of Upper Aerodigestive Malignancies
Johns Hopkins University School of Medicine
Baltimore, Maryland

Dr. Forde treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Associate Member of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Director of Clinical Research for lung cancer, mesothelioma, and other thoracic cancers at Johns Hopkins.

He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for earlier stage lung cancer and his work has led to the development of several ongoing phase 3 trials. 

He leads several international phase 2 and 3 clinical trials of novel immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America while also serving as principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins. He is focused on providing compassionate, state of the art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners and dedicated staff.

LEARNING OBJECTIVES

1.
Integrate clinical trial data, expert insights and guidance regarding neoadjuvant immunotherapy into treatment considerations  for patients with early-stage NSCLC.
2.
Integrate clinical trial data, expert insights and guidance regarding adjuvant immunotherapy into treatment considerations for patients with early-stage NSCLC.
3.
Identify immune-related adverse events in patients with early-stage NSCLC being treated with neoadjuvant/perioperative or adjuvant immunotherapy.
4.
Implement strategies to mitigate or manage immune-related toxicities in patients with early-stage NSCLC being treated with neoadjuvant/perioperative or adjuvant immunotherapy.